X
[{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiho and Lung Therapeutics Enter into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lung Therapeutics Announces Successful Completion of Phase 1a Clinical Trial of LTI-03 in Healthy Volunteers","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Aileron Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aileron Therapeutics Announces Acquisition of Lung Therapeutics","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Lung Therapeutics
Filters
Companies By Therapeutic Area
Details:
The acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF).
Lead Product(s):
LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: LTI-03
Highest Development Status: Phase I
Product Type: Peptide
Partner/Sponsor/Collaborator:
Aileron Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
October 31, 2023
Details:
The phase 1a clinical trial assessed ascending doses of LTI-03,, a Caveolin-1-related peptide in healthy normal volunteers. LTI-03 dose levels from 2.5 mg to 10 mg appeared to be safe and well tolerated with no reports of discontinuations or serious adverse events.
Lead Product(s):
Caveolin-1-scaffolding Protein-derived Peptide
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: LTI-03
Highest Development Status: Phase I
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 22, 2022
Details:
Under the terms of the agreement, Taiho will obtain the rights for the development and commercialization of LTI-01 in Japan. Lung Tx will receive an upfront payment, milestone, and royalty payments based on product sales.
Lead Product(s):
LTI-01
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: LTI-01
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Taiho Pharmaceutical
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
November 12, 2020